Inferensys

Glossary

Limit of Detection (LoD)

The lowest concentration of analyte that can be reliably distinguished from background noise, defining the analytical sensitivity floor of a liquid biopsy assay.
Security analyst reviewing fraud detection AI on multiple screens, alert dashboards visible, dark mode monitoring setup.
ANALYTICAL SENSITIVITY

What is Limit of Detection (LoD)?

The Limit of Detection (LoD) defines the lowest analyte concentration that can be reliably distinguished from the absence of that analyte (a blank sample) with a defined statistical confidence, establishing the analytical sensitivity floor of a measurement procedure.

The Limit of Detection (LoD) is the lowest concentration of an analyte—such as circulating tumor DNA (ctDNA)—that an assay can reliably distinguish from background noise at a specified confidence level, typically 95%. It is empirically determined by measuring replicates of a blank sample and a low-concentration sample, then calculating the signal threshold above which a positive detection is statistically distinct from zero. LoD is distinct from the Limit of Quantification (LoQ), which defines the lowest concentration measurable with acceptable precision and accuracy.

In liquid biopsy analytics, LoD is often expressed as the minimum Variant Allele Frequency (VAF) detectable in a cell-free DNA sample, frequently targeting 0.1% or lower for early cancer detection. Achieving an ultra-low LoD requires error-suppression techniques such as Unique Molecular Identifiers (UMIs) and duplex sequencing to distinguish true somatic variants from polymerase errors and base damage. The LoD directly constrains clinical sensitivity, as a tumor must shed sufficient ctDNA to exceed this threshold for a positive result.

ANALYTICAL SENSITIVITY DRIVERS

Key Determinants of LoD in Liquid Biopsy

The Limit of Detection (LoD) is not a single fixed number but a dynamic threshold governed by the interplay of molecular biology, sequencing chemistry, and computational noise suppression. The following factors collectively define the lowest concentration of analyte that can be reliably distinguished from background noise.

01

Input Molecule Quantity

The absolute number of amplifiable genome equivalents (GE) extracted from plasma is the fundamental ceiling on sensitivity. LoD is mathematically constrained by Poisson sampling statistics: if a mutation is present at 0.1% VAF, a minimum of ~3,000 GE must be interrogated to reliably capture at least one mutant molecule. Low-yield extractions from limited plasma volumes directly degrade the assay's ability to resolve rare variants, regardless of downstream error correction.

~3,000 GE
Min. input for 0.1% LoD
02

Background Error Rate

The systematic noise floor of the assay, arising from polymerase errors during library amplification, oxidative DNA damage, and sequencer base-calling inaccuracies. A variant is only detectable when its signal exceeds this noise. Standard NGS workflows exhibit error rates of ~0.1–1%, which obscures low-frequency ctDNA. Reducing this rate via molecular barcoding and specialized polymerases is the primary engineering challenge for improving LoD.

0.1–1%
Standard NGS error rate
04

Sequencing Depth & Breadth

Dedicated sequencing depth—the number of times a given base is read—is directly proportional to the power to resolve low-frequency variants. To confidently call a variant at 0.01% VAF, a unique depth of >10,000x is typically required after deduplication. This often necessitates targeted panel sequencing rather than whole-genome approaches, trading genomic breadth for the extreme depth necessary to achieve a clinically actionable LoD.

>10,000x
Unique depth for 0.01% LoD
05

Allelic Dropout & Sampling Bias

A stochastic phenomenon where a true variant molecule is not captured, amplified, or sequenced due to chance. This is most severe at very low input quantities and can cause false negatives even when the mean expected number of mutant molecules is >1. LoD calculations must account for the probability of dropout, often modeled via binomial or Poisson statistics, to define the concentration at which a variant is detected with 95% confidence.

06

Computational Noise Filtering

Bioinformatic pipelines apply a series of filters to distinguish signal from artifact. Key steps include:

  • Base Quality Recalibration (BQR): Adjusts sequencer quality scores using machine learning models of error covariates.
  • Panel of Normals (PoN): Suppresses recurrent technical artifacts identified in healthy control samples.
  • Germline Filtering: Subtracts inherited polymorphisms using matched normal DNA or population databases.
  • Positional Bias Models: Corrects for strand-specific and cycle-specific errors. The rigor of these filters directly impacts the achievable LoD.
ANALYTICAL SENSITIVITY

Frequently Asked Questions

Clarifying the statistical and practical boundaries of detecting rare biomarkers in a high-background environment.

The Limit of Detection (LoD) is the lowest concentration of an analyte—such as circulating tumor DNA (ctDNA) or a specific somatic variant—that can be reliably distinguished from background noise with a defined statistical confidence, typically 95%. It defines the analytical sensitivity floor of the assay. Unlike the Limit of Blank (LoB), which characterizes the signal distribution of negative control samples, the LoD is established by serially diluting a known positive sample into a negative matrix until the signal is no longer consistently distinguishable from the LoB. In liquid biopsy, LoD is often expressed as a Variant Allele Frequency (VAF) percentage (e.g., 0.1% VAF) or as mutant molecule copies per milliliter of plasma. A robust LoD determination requires accounting for library complexity, Unique Molecular Identifier (UMI) recovery, and the stochastic sampling error inherent to low-input DNA quantities.

ANALYTICAL SENSITIVITY BENCHMARKS

LoD Comparison Across Liquid Biopsy Technologies

Comparison of limit of detection capabilities, error suppression mechanisms, and clinical applicability across major liquid biopsy analytical platforms for circulating tumor DNA analysis.

FeatureDigital Droplet PCR (ddPCR)NGS with UMIsDuplex Sequencing

Typical LoD (VAF)

0.01% - 0.1%

0.1% - 0.5%

0.001% - 0.01%

Error Suppression Mechanism

Poisson statistics and partitioning

Molecular barcode consensus

Dual-strand consensus

Single Nucleotide Variant Detection

Copy Number Alteration Detection

Multiplexing Capacity

1-5 targets

50-500+ genes

50-500+ genes

Absolute Quantification

Fragmentomics Analysis

Input DNA Required

1-10 ng

10-50 ng

50-100 ng

Prasad Kumkar

About the author

Prasad Kumkar

CEO & MD, Inference Systems

Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.

His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.